Login to Your Account



Bench Press: BioWorld Looks at Translational Medicine


Monday, August 27, 2012
Scientists from the University of California at San Francisco and Memorial Sloan-Kettering Cancer Center have used sequencing data from a single patient to identify mutations in the tuberous sclerosis complex 1 gene as a biomarker that can predict the response to the mTOR inhibitor Afinitor (everolimus, Novartis AG).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription